Scarica l'app Stockscreener
22.76
0.93%
-0.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$23.06
Aprire:
$23.87
Volume 24 ore:
846.26K
Relative Volume:
0.41
Capitalizzazione di mercato:
$17.01B
Reddito:
$956.00K
Utile/perdita netta:
$-196.68M
Rapporto P/E:
-94.83
EPS:
-0.24
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
+6.90%
1M Prestazione:
+3.37%
6M Prestazione:
+71.25%
1 anno Prestazione:
+455.84%
Intervallo 1D:
$22.72
$24.18
Intervallo di 1 settimana:
$20.43
$24.18
Portata 52W:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.77 | 17.01B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.12 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.76 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.81 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.97 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.60 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Summit Therapeutics (SMMT) Expected to Announce Earnings on Tuesday - MarketBeat
Summit Therapeutics Earnings: Critical Q4 Financial Report & Strategic Roadmap Reveal Coming February 24 - StockTitan
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.8%Time to Sell? - MarketBeat
3 Stocks That Could Trounce the Market in 2025 - Yahoo Finance
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8%Here's What Happened - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6%Here's Why - MarketBeat
SG Americas Securities LLC Sells 19,587 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
When the Price of (SMMT) Talks, People Listen - Stock Traders Daily
abrdn plc Increases Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024 - Citeline News & Insights
Calamos Advisors LLC Has $425,000 Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
2 Stocks That Could Soar Again in 2025 - MSN
Why Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4%Should You Sell? - MarketBeat
The drug industry is having its own DeepSeek moment | Mint - Mint
The Drug Industry Is Having Its Own DeepSeek Moment - The Wall Street Journal
China Universal Asset Management Co. Ltd. Acquires 17,014 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Brokerages - MarketBeat
Five Pine Wealth Management Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (SMMT): Jim Cramer Calls It a ‘Very Big Spec’ - Insider Monkey
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' - Benzinga India
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - MSN
Griffin Asset Management Inc. Purchases 42,900 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Lightning Round: I don't want to sell Adobe down here, says Jim Cramer - MSN
(SMMT) Investment Report - Stock Traders Daily
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - The Motley Fool
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.09%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):